Sonntag, 1. August 2021
Navigation öffnen
Anzeige:
Imfinzi NSCLC
Imfinzi NSCLC
JOURNAL ONKOLOGIE – STUDIE
NIRBTEST

New Strategies to Detect Cancers in Carriers of Mutations in RB1

Rekrutierend

NCT-Nummer:
NCT04164134

Studienbeginn:
Dezember 2018

Letztes Update:
02.04.2021

Wirkstoff:
-

Indikation (Clinical Trials):
Retinoblastoma, Neoplasms

Geschlecht:
Alle

Altersgruppe:
Alle

Phase:
-

Sponsor:
VU University Medical Center

Collaborator:
University Hospital, Essen, Institut Curie, Ligue contre le cancer, France,

Studienleiter

Armida Fabius
Principal Investigator
VUMC

Kontakt

Studienlocations
(3 von 3)

Studien-Informationen

Brief Summary:

Rationale: Individuals with a cancer predisposition due to a mutation in the paradigm tumor

suppressor gene RB1, have a high risk to develop the childhood cancer retinoblastoma (Rb).

Biopsies are not possible in Rb, before treatment selection. Heritable Rb patients have also

a high risk to develop other types of second primary, either childhood or adult, malignancies

(SPMs), notably sarcomas and melanomas. Remarkably, SPMs are now the leading cause of death

in heritable-Rb-survivors. Unfortunately, there are no well-developed regular surveillance

protocols for SPMs in Rb survivors available right now. Recently, new non-invasive cancer

test have been developed, based on either RNA-sequencing data from platelets (ThromboSeq), or

on extracellular membrane vesicles (EVs) derived from tumor cells present in blood.

Objective:

- Determine the non-cancerous baseline in adult RB1-mutation carriers

(heritable-Rb-survivors).

- Contribute to the biobanking of blood and cancerous tissues from RB1-mutation carriers

with SPMs.

- The development of blood-based tests, either platelet or EV-based, for the detection of

(the type of) tumors in RB1-mutation carriers.

Study design: Cross-sectional multicenter trial.

Study population:

- 40 Rb patients (children),

- 40 controls (children),

- 153 Rb survivors (adults),

- 153 controls (adults),

- 10 Rb survivors with SPM (children/adults).

Main study parameters/endpoints:

- Determine the non-cancerous baseline in adult RB1-mutation carriers

(heritable-Rb-survivors).

- Contribute to the biobanking of blood and cancerous tissues from RB1-mutation carriers

with SPMs.

Nature and extent of the burden and risks associated with participation, benefit and group

relatedness:

Two blood samples totalling 10ml blood will be collected for every participant. Additionally,

a short questionnaire has to be filled in concerning their and their family's cancer history.

Blood draws will be done, when participants are already present in the hospital for other

appointments, and thus no extra visits are required. For all children, blood will be

collected through an already present IV, and so no extra venepuncture is required. Children

have to be included because Rb is a tumor only present in this patient group.

Ein-/Ausschlusskriterien

Inclusion Criteria:

Adult (16 years and older):

- Group 1: germline mutation RB1.

- Group 2 (control): no germline mutation RB1.

Pediatric (until 6 years of age):

- Group 1: somatic or germline mutation RB1 and retinoblastoma.

- Group 2 (control): no mutation RB1.

Exclusion Criteria:

Adult (16 years and older):

- Group 1: concomitant heritable (inherited) disorder other than caused by monoallelic

mutation of RB1.

- Group 2 (control): cancer or already known cancer predisposition syndrome.

Pediatric (until 6 years of age):

- Group 1: concomitant heritable (inherited) disorder other than caused by monoallelic

mutation of RB1.

- Group 2: cancer or already known cancer predisposition syndrome.

Studien-Rationale

Primary outcome:

1. RNA expression on platelets and allelic DNA balance of EVs in the blood of adult RB1 mutation carriers (Rb-survivors) and retinoblastoma patients (children). (Time Frame - blood will be taken at study inclusion, patients will be followed throughout the study, max 3 years and 9 months.):
blood analyses at time of inclusion to determine baseline



Secondary outcome:

1. RNA expression on platelets, allelic DNA balance of EVs in blood and genomic analysis on tumor tissue of RB1-mutation carriers diagnosed with a second primary malignancy. (Time Frame - blood will be taken at study inclusion, patients will be followed throughout the study, max 3 years and 9 months. In case of second primary tumor a second sample will be taken.):
Comparison of blood at time of inclusion and blood at time of SPM diagnosis versus tumor tissue (if available)

Studien-Arme

  • Retinoblastoma patients (children)
    Children that are currently diagnosed with a retinoblastoma. Blood will be collected and a short questionnaire has to be filled by the parent or legal guardian. Samples will be taken together with standard care blood draw, so no extra venepuncture is required.
  • Controls (children)
    Children with an unrelated problem/condition for which surgery is needed Blood will be collected and a short questionnaire has to be filled by the parent or legal guardian. Samples will be taken during standard care blood draw, so no extra venepuncture is required.
  • Retinoblastoma survivors (adults)
    Adults that carry a RB1 germline mutation and were diagnosed and treated for retinoblastoma in the past. Blood will be collected and a short questionnaire has to be filled.
  • Controls (adults)
    Healthy adult controls Blood will be collected and a short questionnaire has to be filled.
  • Retinoblastoma survivors with Secondary primary malignancies
    Adults that carry a RB1 germline mutation, were treated for retinoblastoma in the past, and are currently diagnosed with a secondary primary malignancy. Blood will be collected and a short questionnaire has to be filled. Tumor tissue will be collected during surgery.

Geprüfte Regime

  • blood draw:
    Control samples for the Rb survivor group (adult) are already available at the VUMC for the platelet study; unselected volunteers from an anti-cancer campaign. Control samples (adult) for the EV study will be collected in a blooddrive at the Essen site. Pediatric patients. For the pediatric Rb patients, blood draw is part of standard care (3mth-4y). The control blood samples of healthy children (12) will be drawn from healthy children, where the blood draw is already part of otherwise planned care (e.g. patients which are completely healthy besides having an unrelated problem for which surgery is required). Controls will be age-matched as much as possible.

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
EHA 2021
  • SCD: Häufigere und längere VOC-bedingte Krankenhausaufenthalte nach Vorgeschichte von VOC-Hospitalisierungen – Ergebnisse einer Beobachtungsstudie
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Französische Real-World-Studie: Eltrombopag meist frühzeitig nach ITP-Diagnose im Rahmen eines Off-label-Use eingesetzt
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose